MovDisordV3, PascalFrancis, Curation, bibRecord, 002207

Onset of Dyskinesia with Adjunct Ropinirole Prolonged-Release or Additional Levodopa in Early Parkinson's Disease

Identifieur interne : 002207 ( PascalFrancis/Curation ); précédent : 002206; suivant : 002208

Onset of Dyskinesia with Adjunct Ropinirole Prolonged-Release or Additional Levodopa in Early Parkinson's Disease

Auteurs : Ray L. Watts [États-Unis] ; Kelly E. Lyons [États-Unis] ; Rajesh Pahwa [États-Unis] ; Kapil Sethi [États-Unis] ; Matthew Stern [États-Unis] ; Robert A. Hauser [États-Unis] ; Warren Olanow [États-Unis] ; Alex M. Gray [États-Unis] ; Bryan Adams [États-Unis] ; Nancy L. Earl [États-Unis]

Source :

Movement disorders [ 0885-3185 ] ; 2010.

RBID : Pascal:10-0288345

Descripteurs français

Pascal (Inist)
- Dyskinésie, Maladie de Parkinson, Pathologie du système nerveux, Ropinirole, Libération, Lévodopa.

English descriptors

KwdEn :
- Dyskinesia, Levodopa, Nervous system diseases, Parkinson disease, Release, Ropinirole.

Abstract

Levodopa-induced dyskinesia can result in significant functional disability and reduced quality of life in patients with Parkinson's disease (PD). The goal of this study was to determine if the addition of once-daily ropinirole 24-hour prolonged-release (n = 104) in PD patients not optimally controlled with levodopa after up to 3 years of therapy with less than 600 mg/d delays the onset of dyskinesia compared with increasing doses of levodopa (n = 104). During the study, 3% of the ropinirole prolonged-release group (mean dose 10 mg/d) and 17% of the levodopa group (mean additional dose 284 mg/d) developed dyskinesia (P < 0.001). There were no significant differences in change in Unified Parkinson's Disease Rating Scale activities of daily living or motor scores, suggesting comparable efficacy between the two treatments. Adverse events were comparable in the two groups with nausea, dizziness, insomnia, back pain, arthralgia, somnolence, fatigue, and pain most commonly reported. Ropinirole prolonged-release delayed the onset of dyskinesia with comparable efficacy to increased doses of levodopa in early PD patients not optimally controlled with levodopa.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 25`
A06				`@2 7`
A08	`01`	`1`	`ENG`	`@1 Onset of Dyskinesia with Adjunct Ropinirole Prolonged-Release or Additional Levodopa in Early Parkinson's Disease`
A11	`01`	`1`		`@1 WATTS (Ray L.)`
A11	`02`	`1`		`@1 LYONS (Kelly E.)`
A11	`03`	`1`		`@1 PAHWA (Rajesh)`
A11	`04`	`1`		`@1 SETHI (Kapil)`
A11	`05`	`1`		`@1 STERN (Matthew)`
A11	`06`	`1`		`@1 HAUSER (Robert A.)`
A11	`07`	`1`		`@1 OLANOW (Warren)`
A11	`08`	`1`		`@1 GRAY (Alex M.)`
A11	`09`	`1`		`@1 ADAMS (Bryan)`
A11	`10`	`1`		`@1 EARL (Nancy L.)`
A14	`01`			`@1 Department of Neurology, University of Alabama at Birmingham @2 Birmingham, Alabama @3 USA @Z 1 aut.`
A14	`02`			`@1 Department of Neurology, University of Kansas Medical Center @2 Kansas City, Kansas @3 USA @Z 2 aut. @Z 3 aut.`
A14	`03`			`@1 Department of Neurology, Medical College of Georgia @2 Augusta, Georgia @3 USA @Z 4 aut.`
A14	`04`			`@1 Department of Neurology, University of Pennsylvania/Pennsylvania Hospital @2 Philadelphia, Pennsylvania @3 USA @Z 5 aut.`
A14	`05`			`@1 Department of Neurology, University of South Florida @2 Tampa, Florida @3 USA @Z 6 aut.`
A14	`06`			`@1 Department of Neurology, Mount Sinai Medical Center @2 New York, New York @3 USA @Z 7 aut.`
A14	`07`			`@1 Division of Neurosciences, US Clinical, GlaxoSmithKline @2 Research Triangle Park, North Carolina @3 USA @Z 8 aut. @Z 9 aut. @Z 10 aut.`
A17	`01`	`1`		`@1 228 Study Investigators @3 INC`
A20				`@1 858-866`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000193040220070`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 25 ref.`
A47	`01`	`1`		`@0 10-0288345`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Levodopa-induced dyskinesia can result in significant functional disability and reduced quality of life in patients with Parkinson's disease (PD). The goal of this study was to determine if the addition of once-daily ropinirole 24-hour prolonged-release (n = 104) in PD patients not optimally controlled with levodopa after up to 3 years of therapy with less than 600 mg/d delays the onset of dyskinesia compared with increasing doses of levodopa (n = 104). During the study, 3% of the ropinirole prolonged-release group (mean dose 10 mg/d) and 17% of the levodopa group (mean additional dose 284 mg/d) developed dyskinesia (P < 0.001). There were no significant differences in change in Unified Parkinson's Disease Rating Scale activities of daily living or motor scores, suggesting comparable efficacy between the two treatments. Adverse events were comparable in the two groups with nausea, dizziness, insomnia, back pain, arthralgia, somnolence, fatigue, and pain most commonly reported. Ropinirole prolonged-release delayed the onset of dyskinesia with comparable efficacy to increased doses of levodopa in early PD patients not optimally controlled with levodopa.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Dyskinésie @5 01`
C03	`01`	`X`	`ENG`	`@0 Dyskinesia @5 01`
C03	`01`	`X`	`SPA`	`@0 Disquinesia @5 01`
C03	`02`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 03`
C03	`03`	`X`	`ENG`	`@0 Nervous system diseases @5 03`
C03	`03`	`X`	`SPA`	`@0 Sistema nervioso patología @5 03`
C03	`04`	`X`	`FRE`	`@0 Ropinirole @2 NK @2 FR @5 09`
C03	`04`	`X`	`ENG`	`@0 Ropinirole @2 NK @2 FR @5 09`
C03	`04`	`X`	`SPA`	`@0 Ropinirol @2 NK @2 FR @5 09`
C03	`05`	`X`	`FRE`	`@0 Libération @5 10`
C03	`05`	`X`	`ENG`	`@0 Release @5 10`
C03	`05`	`X`	`SPA`	`@0 Liberación @5 10`
C03	`06`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 11`
C03	`06`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 11`
C03	`06`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 11`
C07	`01`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 37`
C07	`01`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 37`
C07	`01`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 37`
C07	`02`	`X`	`FRE`	`@0 Mouvement involontaire @5 38`
C07	`02`	`X`	`ENG`	`@0 Involuntary movement @5 38`
C07	`02`	`X`	`SPA`	`@0 Movimiento involuntario @5 38`
C07	`03`	`X`	`FRE`	`@0 Trouble neurologique @5 40`
C07	`03`	`X`	`ENG`	`@0 Neurological disorder @5 40`
C07	`03`	`X`	`SPA`	`@0 Trastorno neurológico @5 40`
C07	`04`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 41`
C07	`04`	`X`	`ENG`	`@0 Cerebral disorder @5 41`
C07	`04`	`X`	`SPA`	`@0 Encéfalo patología @5 41`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 42`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 42`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 42`
C07	`06`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 43`
C07	`06`	`X`	`ENG`	`@0 Central nervous system disease @5 43`
C07	`06`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 43`
N21				`@1 186`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000B12

Links to Exploration step

Pascal:10-0288345

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Onset of Dyskinesia with Adjunct Ropinirole Prolonged-Release or Additional Levodopa in Early Parkinson's Disease</title>
<author><name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University of Alabama at Birmingham</s1>
<s2>Birmingham, Alabama</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Lyons, Kelly E" sort="Lyons, Kelly E" uniqKey="Lyons K" first="Kelly E." last="Lyons">Kelly E. Lyons</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Pahwa, Rajesh" sort="Pahwa, Rajesh" uniqKey="Pahwa R" first="Rajesh" last="Pahwa">Rajesh Pahwa</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Sethi, Kapil" sort="Sethi, Kapil" uniqKey="Sethi K" first="Kapil" last="Sethi">Kapil Sethi</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, Medical College of Georgia</s1>
<s2>Augusta, Georgia</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Stern, Matthew" sort="Stern, Matthew" uniqKey="Stern M" first="Matthew" last="Stern">Matthew Stern</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Neurology, University of Pennsylvania/Pennsylvania Hospital</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Olanow, Warren" sort="Olanow, Warren" uniqKey="Olanow W" first="Warren" last="Olanow">Warren Olanow</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Neurology, Mount Sinai Medical Center</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Gray, Alex M" sort="Gray, Alex M" uniqKey="Gray A" first="Alex M." last="Gray">Alex M. Gray</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Division of Neurosciences, US Clinical, GlaxoSmithKline</s1>
<s2>Research Triangle Park, North Carolina</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Adams, Bryan" sort="Adams, Bryan" uniqKey="Adams B" first="Bryan" last="Adams">Bryan Adams</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Division of Neurosciences, US Clinical, GlaxoSmithKline</s1>
<s2>Research Triangle Park, North Carolina</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Earl, Nancy L" sort="Earl, Nancy L" uniqKey="Earl N" first="Nancy L." last="Earl">Nancy L. Earl</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Division of Neurosciences, US Clinical, GlaxoSmithKline</s1>
<s2>Research Triangle Park, North Carolina</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0288345</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0288345 INIST</idno>
<idno type="RBID">Pascal:10-0288345</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000B12</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002207</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Onset of Dyskinesia with Adjunct Ropinirole Prolonged-Release or Additional Levodopa in Early Parkinson's Disease</title>
<author><name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, University of Alabama at Birmingham</s1>
<s2>Birmingham, Alabama</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Lyons, Kelly E" sort="Lyons, Kelly E" uniqKey="Lyons K" first="Kelly E." last="Lyons">Kelly E. Lyons</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Pahwa, Rajesh" sort="Pahwa, Rajesh" uniqKey="Pahwa R" first="Rajesh" last="Pahwa">Rajesh Pahwa</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Sethi, Kapil" sort="Sethi, Kapil" uniqKey="Sethi K" first="Kapil" last="Sethi">Kapil Sethi</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, Medical College of Georgia</s1>
<s2>Augusta, Georgia</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Stern, Matthew" sort="Stern, Matthew" uniqKey="Stern M" first="Matthew" last="Stern">Matthew Stern</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Neurology, University of Pennsylvania/Pennsylvania Hospital</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Olanow, Warren" sort="Olanow, Warren" uniqKey="Olanow W" first="Warren" last="Olanow">Warren Olanow</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Neurology, Mount Sinai Medical Center</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Gray, Alex M" sort="Gray, Alex M" uniqKey="Gray A" first="Alex M." last="Gray">Alex M. Gray</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Division of Neurosciences, US Clinical, GlaxoSmithKline</s1>
<s2>Research Triangle Park, North Carolina</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Adams, Bryan" sort="Adams, Bryan" uniqKey="Adams B" first="Bryan" last="Adams">Bryan Adams</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Division of Neurosciences, US Clinical, GlaxoSmithKline</s1>
<s2>Research Triangle Park, North Carolina</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Earl, Nancy L" sort="Earl, Nancy L" uniqKey="Earl N" first="Nancy L." last="Earl">Nancy L. Earl</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Division of Neurosciences, US Clinical, GlaxoSmithKline</s1>
<s2>Research Triangle Park, North Carolina</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dyskinesia</term>
<term>Levodopa</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Release</term>
<term>Ropinirole</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dyskinésie</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Ropinirole</term>
<term>Libération</term>
<term>Lévodopa</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Levodopa-induced dyskinesia can result in significant functional disability and reduced quality of life in patients with Parkinson's disease (PD). The goal of this study was to determine if the addition of once-daily ropinirole 24-hour prolonged-release (n = 104) in PD patients not optimally controlled with levodopa after up to 3 years of therapy with less than 600 mg/d delays the onset of dyskinesia compared with increasing doses of levodopa (n = 104). During the study, 3% of the ropinirole prolonged-release group (mean dose 10 mg/d) and 17% of the levodopa group (mean additional dose 284 mg/d) developed dyskinesia (P < 0.001). There were no significant differences in change in Unified Parkinson's Disease Rating Scale activities of daily living or motor scores, suggesting comparable efficacy between the two treatments. Adverse events were comparable in the two groups with nausea, dizziness, insomnia, back pain, arthralgia, somnolence, fatigue, and pain most commonly reported. Ropinirole prolonged-release delayed the onset of dyskinesia with comparable efficacy to increased doses of levodopa in early PD patients not optimally controlled with levodopa.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>25</s2>
</fA05>
<fA06><s2>7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Onset of Dyskinesia with Adjunct Ropinirole Prolonged-Release or Additional Levodopa in Early Parkinson's Disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>WATTS (Ray L.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LYONS (Kelly E.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>PAHWA (Rajesh)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SETHI (Kapil)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>STERN (Matthew)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>HAUSER (Robert A.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>OLANOW (Warren)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>GRAY (Alex M.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>ADAMS (Bryan)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>EARL (Nancy L.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, University of Alabama at Birmingham</s1>
<s2>Birmingham, Alabama</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology, University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurology, Medical College of Georgia</s1>
<s2>Augusta, Georgia</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Neurology, University of Pennsylvania/Pennsylvania Hospital</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Neurology, University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Neurology, Mount Sinai Medical Center</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Division of Neurosciences, US Clinical, GlaxoSmithKline</s1>
<s2>Research Triangle Park, North Carolina</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>228 Study Investigators</s1>
<s3>INC</s3>
</fA17>
<fA20><s1>858-866</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000193040220070</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>25 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0288345</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Levodopa-induced dyskinesia can result in significant functional disability and reduced quality of life in patients with Parkinson's disease (PD). The goal of this study was to determine if the addition of once-daily ropinirole 24-hour prolonged-release (n = 104) in PD patients not optimally controlled with levodopa after up to 3 years of therapy with less than 600 mg/d delays the onset of dyskinesia compared with increasing doses of levodopa (n = 104). During the study, 3% of the ropinirole prolonged-release group (mean dose 10 mg/d) and 17% of the levodopa group (mean additional dose 284 mg/d) developed dyskinesia (P < 0.001). There were no significant differences in change in Unified Parkinson's Disease Rating Scale activities of daily living or motor scores, suggesting comparable efficacy between the two treatments. Adverse events were comparable in the two groups with nausea, dizziness, insomnia, back pain, arthralgia, somnolence, fatigue, and pain most commonly reported. Ropinirole prolonged-release delayed the onset of dyskinesia with comparable efficacy to increased doses of levodopa in early PD patients not optimally controlled with levodopa.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Ropinirole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Ropinirole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Ropinirol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Libération</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Release</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Liberación</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>40</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>40</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>41</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>41</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>43</s5>
</fC07>
<fN21><s1>186</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002207 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 002207 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:10-0288345
   |texte=   Onset of Dyskinesia with Adjunct Ropinirole Prolonged-Release or Additional Levodopa in Early Parkinson's Disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Onset of Dyskinesia with Adjunct Ropinirole Prolonged-Release or Additional Levodopa in Early Parkinson's Disease

Onset of Dyskinesia with Adjunct Ropinirole Prolonged-Release or Additional Levodopa in Early Parkinson's Disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri